CClinicalTrials.gg
Status unknownNCT04570007Updated Oct 27, 2021

Vitreous Fragments Length After Pars Plana Vitrectomy

An observational study in Vitreous Disorder and Vitreous Anomalies, sponsored by Ospedale Policlinico San Martino. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-10-27.

Sponsored by Ospedale Policlinico San Martino · Observational

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 90 Years
Sex
All
01

Study summary

To measure vitreous collagen fragments length after pars plana vitrectomy performed at different cut rates

Read the detailed description

Pars plana vitrectomy consists in the removal of vitreous obtained with a vitreous cutter. The instruments attracts vitreous in its port through active suction and cuts with a blade at different cut rates. There is no consensus as to which cut rate would be ideal in order to minimize traction, neither there is agreement on whether increasing cut rates generate shorter collagen fragments or the fluid turbulence creates unpredictable flows at the port generating fragments of different length.

The investigators plan to gather vitreous cut at 1,000, 2,000, 4,000, 8,000 and 16,000 cuts per minute and measure vitreous collagen average length

02

Conditions studied

  • Vitreous Disorder
  • Vitreous Anomalies
03

In context

Lead sponsor

Ospedale Policlinico San Martino is the lead sponsor of 30 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

patients over 18 undergoing pars plana vitrectomy for macular surgery or retinal detachment

Inclusion criteria

  • patient undergoing pars plana vitrectomy for:
  • macular pucker
  • macular hole-
  • retinal detachment
  • age >18

Exclusion criteria

Exclusion Criteria:

  • unwilling to participate
  • previous trauma
  • vitreous haemorrhage
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • ProcedurePars Plana Vitrectomy

    removal of vitreous with vitreous cutter

06

What researchers measure

Primary outcomes

  1. collagen fragment molecular weigth

    collagen passed through the vitreous cutter is examined with regard to collagen moecular weigth

    Time frame: at time of surgery

07

Study locations

1 of 1 sites recruiting
  • IRCCS Policlinico San Martino
    Genova, RM 16100, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04570007
Lead sponsor
Ospedale Policlinico San Martino
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
Sep 20, 2020
Primary completion
Oct 30, 2021 (estimated)
Completion
Dec 10, 2021 (estimated)
Last update
Oct 27, 2021

Study contacts

Tommaso Rossi
Contact
tommaso.rossi024@gmail.com
+393482645034
Tommaso Rossi
principal investigator · IRCCS Policlinico San MArtino

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion